Veracyte, Inc. (VCYT)Healthcare | Diagnostics & Research | South San Francisco, United States | NasdaqGM
43.34 USD
-1.91
(-4.221%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 44.20 +0.86 (1.984%) ⇧ (Aug. 28, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:44 a.m. EDT
Veracyte presents a classic 'value trap' scenario where strong historical growth masks deteriorating recent momentum. The company boasts an impressive long-term track record with nearly five-fold gains over nine years and robust revenue growth, supported by a fortress-like balance sheet featuring massive liquidity and negligible debt. However, the market has punished the stock recently, with the price trading below its 200-day moving average and showing a trailing run of negative annual returns. While the forward P/E suggests earnings recovery is priced in, the technical setup remains weak. The options market reflects this uncertainty, with traders hedging downside risks while waiting for a catalyst to justify the higher strike prices. This is a hold for patient investors who believe in the long-term thesis, but a risky entry for those seeking immediate momentum. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.063196 |
| MSTL | 0.124989 |
| AutoETS | 0.125399 |
| AutoARIMA | 0.137168 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 23.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.889 |
| Revenue per Share | 7.081 |
| Market Cap | 3,484,134,144 |
| Trailing P/E | 32.34 |
| Forward P/E | 22.25 |
| Beta | 1.94 |
| Profit Margins | 20.37% |
| Website | https://www.veracyte.com |
As of Aug. 22, 2026, 2:44 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a decisive breakout. In the near term (August expiration), there is heavy put volume at strikes significantly below the current price, suggesting a hedge against further downside, while call interest is concentrated at strikes well above the current level. For longer-dated expirations, open interest is heavily skewed toward out-of-the-money calls, indicating a speculative bet on a significant rally, yet the lack of immediate volume suggests this is a passive positioning strategy rather than active aggressive buying.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.502823 |
| Address1 | 6,000 Shoreline Court |
| Address2 | Suite 300 |
| All Time High | 86.03 |
| All Time Low | 4.21 |
| Ask | 59.52 |
| Ask Size | 2 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,396,410 |
| Average Daily Volume3 Month | 1,361,661 |
| Average Volume | 1,361,661 |
| Average Volume10Days | 1,396,410 |
| Beta | 1.94 |
| Bid | 33.3 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 17.276 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 43.34 |
| Current Ratio | 9.162 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 45.55 |
| Day Low | 43.32 |
| Debt To Equity | 2.889 |
| Display Name | Veracyte |
| Earnings Call Timestamp End | 1,785,443,400 |
| Earnings Call Timestamp Start | 1,785,443,400 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | 113,515,000 |
| Ebitda Margins | 0.20201999 |
| Enterprise To Ebitda | 26.772 |
| Enterprise To Revenue | 5.408 |
| Enterprise Value | 3,039,009,280 |
| Eps Current Year | 1.90636 |
| Eps Forward | 1.94818 |
| Eps Trailing Twelve Months | 1.34 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 243 6388 |
| Fifty Day Average | 52.0101 |
| Fifty Day Average Change | -8.670101 |
| Fifty Day Average Change Percent | -0.16670033 |
| Fifty Two Week Change Percent | 50.2823 |
| Fifty Two Week High | 60.91 |
| Fifty Two Week High Change | -17.57 |
| Fifty Two Week High Change Percent | -0.28845838 |
| Fifty Two Week Low | 29.375 |
| Fifty Two Week Low Change | 13.965 |
| Fifty Two Week Low Change Percent | 0.47540426 |
| Fifty Two Week Range | 29.375 - 60.91 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,383,139,800,000 |
| Float Shares | 79,878,642 |
| Forward Eps | 1.94818 |
| Forward P E | 22.246405 |
| Free Cashflow | 106,230,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 755 |
| Fullday Change | -1.91 |
| Fullday Change Percent | -4.22099 |
| Fullday Price | 44.2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.73756 |
| Gross Profits | 414,436,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00537 |
| Held Percent Institutions | 1.13482 |
| Implied Shares Outstanding | 80,390,731 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. |
| Long Name | Veracyte, Inc. |
| Market | us_market |
| Market Cap | 3,484,134,144 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_42154124 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 114,483,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,637,680,577 |
| Number Of Analyst Opinions | 11 |
| Open | 45.205 |
| Operating Cashflow | 178,380,992 |
| Operating Margins | 0.15287 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 650 243 6300 |
| Post Market Change | 0.8600006 |
| Post Market Change Percent | 1.9843115 |
| Post Market Price | 44.2 |
| Post Market Time | 1,787,961,077 |
| Previous Close | 45.25 |
| Price Eps Current Year | 22.734425 |
| Price Hint | 2 |
| Price To Book | 2.5086827 |
| Price To Sales Trailing12 Months | 6.2006297 |
| Profit Margins | 0.20374 |
| Quick Ratio | 8.598 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -1.91 |
| Regular Market Change Percent | -4.22099 |
| Regular Market Day High | 45.55 |
| Regular Market Day Low | 43.32 |
| Regular Market Day Range | 43.32 - 45.55 |
| Regular Market Open | 45.205 |
| Regular Market Previous Close | 45.25 |
| Regular Market Price | 43.34 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,684,022 |
| Return On Assets | 0.04093 |
| Return On Equity | 0.087740004 |
| Revenue Growth | 0.155 |
| Revenue Per Share | 7.081 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 80,390,731 |
| Shares Percent Shares Out | 0.0845 |
| Shares Short | 6,789,714 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,674,331 |
| Short Name | Veracyte, Inc. |
| Short Percent Of Float | 0.0998 |
| Short Ratio | 5.17 |
| Source Interval | 15 |
| State | CA |
| Symbol | VCYT |
| Target High Price | 70.0 |
| Target Low Price | 44.0 |
| Target Mean Price | 57.81818 |
| Target Median Price | 55.0 |
| Total Cash | 485,232,000 |
| Total Cash Per Share | 6.036 |
| Total Debt | 40,107,000 |
| Total Revenue | 561,900,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.34 |
| Trailing P E | 32.343285 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 42.567726 |
| Two Hundred Day Average Change | 0.772274 |
| Two Hundred Day Average Change Percent | 0.018142242 |
| Type Disp | Equity |
| Volume | 1,684,022 |
| Website | https://www.veracyte.com |
| Zip | 94,080 |